# A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion

> **NCT04085341** · PHASE2 · COMPLETED · sponsor: **Graybug Vision** · enrollment: 21 (actual)

## Conditions studied

- Diabetic Macular Edema
- Retina Vein Occlusion

## Interventions

- **DRUG:** GB-102

## Key facts

- **NCT ID:** NCT04085341
- **Lead sponsor:** Graybug Vision
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-11
- **Primary completion:** 2020-06-05
- **Final completion:** 2020-06-05
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2021-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04085341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04085341, "A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04085341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*